RESUMEN
Hepatitis Delta Virus (HDV), a satellite virus of Hepatitis B virus, exacerbates liver damage in affected individuals. Screening for HDV antibodies in HBsAg positive patients is recommended, but the diagnostic accuracy of serological tests remains uncertain. This review aimed to assess the diagnostic accuracy of serological tests for HDV. We searched PubMed, Web of Science, Cochrane Central Register of Controlled Trials, Scopus etc. for relevant studies. Studies measuring the sensitivity and specificity of serological HDV tests against PCR as a reference standard were included. Pooled sensitivity and specificity for each test method and sero-marker were calculated. The review included six studies with 11 study arms, evaluating ARCHITECT immunoassay, EIA, ELISA, QMAC, RIA, and Western Blot test methods targeting Anti-HDV IgG, Total anti-HDV and Anti-HDV IgM. Sensitivities for Anti-HDV IgG, Total Anti-HDV and Anti-HDV IgM, tests were 97.4%, 51.9%, and 62.0%, respectively, with specificities of 95.3%, 80.0%, and 85.0%. Our findings, with its limited number of studies, suggest that HDV serological tests, particularly those identifying Anti IgG exhibit high accuracy and can serve as effective screening tools for HDV.
Asunto(s)
Hepatitis D , Virus de la Hepatitis Delta , Sensibilidad y Especificidad , Pruebas Serológicas , Humanos , Virus de la Hepatitis Delta/inmunología , Hepatitis D/diagnóstico , Hepatitis D/virología , Hepatitis D/sangre , Hepatitis D/inmunología , Pruebas Serológicas/métodos , Pruebas Serológicas/normas , Inmunoglobulina G/sangre , Anticuerpos Antihepatitis/sangre , Inmunoglobulina M/sangreRESUMEN
BACKGROUND: Hepatitis-E virus (HEV), an etiologic agent of acute inflammatory liver disease, is a significant cause of morbidity and mortality in South Asia. HEV is considered endemic in Nepal; but data on population-level infection transmission is sparse. METHODS: We conducted a longitudinal serosurvey in central Nepal to assess HEV exposure. At each visit, capillary blood samples were collected and analyzed for the presence of anti-HEV IgG antibodies. The study took place between February 2019 and April 2021, with up to 4 visits per participant approximately 6 months apart. RESULTS: We collected 2513 samples from 923 participants aged 0-25 years, finding a seroprevalence of 4.8% and a seroincidence rate of 10.9 per 1000 person-years. Young adults and individuals consuming surface water faced the highest incidence of infection. Geospatial analysis identified potential HEV clusters, suggesting a need for targeted interventions. SIGNIFICANCE: Our findings demonstrate that HEV is endemic in Nepal and that the risk of infection increases with age.
Asunto(s)
Virus de la Hepatitis E , Hepatitis E , Humanos , Nepal/epidemiología , Hepatitis E/epidemiología , Hepatitis E/sangre , Estudios Seroepidemiológicos , Adolescente , Adulto , Adulto Joven , Virus de la Hepatitis E/inmunología , Niño , Masculino , Femenino , Preescolar , Estudios Longitudinales , Lactante , Inmunoglobulina G/sangre , Anticuerpos Antihepatitis/sangre , Recién Nacido , IncidenciaRESUMEN
Viral hepatitis are infections that can cause liver damage, become chronic, lead to cirrhosis, hepatocellular carcinoma and ultimately result in death due to their ability to spread in the community through blood and infected body fluids. The aim of this study was to determine the seroprevalence of hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV) transmitted through blood among individuals living in Trabzon province and to examine the factors potentially associated with seroprevalence. This cross-sectional study was conducted in Trabzon province, located in the northeast of Türkiye, including a total of 10 districts, including the central district. Since seroprevalence was calculated for HBV, HCV, and HDV in the study, the sample size was separately calculated for each, and the calculated maximum sample size of 1116 was accepted as the minimum sample size for the study. The study was completed with 1502 participants. Serological tests for HBV included HBsAg, anti-HBs, and anti-HBc IgG; for HCV, anti-HCV; and for HDV, anti-HDV were analysed. Data were evaluated for HBV risk factors using univariate analyses with Chi-square test and for multiple analyses using enter model logistic regression analysis. The mean age of the participants was 45.7 ± 16.6 years, with 767 (51.1%) being female. The prevalence of HBV seropositivity, indicating vaccination, was 23.0%, while the seroprevalence of HBV among unvaccinated adults was 27.4%. HBsAg positivity was 5.1%, and isolated anti-HBc IgG positivity was 4.2%. The proportion of individuals with HBsAg in the gray zone was 0.5%, while the positivity rates for anti-HBs and anti-HBc IgG (indicating past infection) were 17.6%. The prevalence of anti-HCV was six per thousand, while anti-HDV was not detected in the analyses. HBsAg positivity and co-infection with HCV were found in one person, and among the nine individuals positive for anti-HCV, isolated anti-HBc IgG positivity was detected in three. Increasing age, presence of a person with jaundice in the family, presence of diabetes mellitus, alcohol use and cupping therapy were identified as risk factors for HBV in the logistic regression analysis. Risk factors for HCV in univariate analyses were being over 40 years old, presence of hepatic steatosis and receiving dialysis treatment. The results of the study indicate that despite being included in our vaccination schedule and the administration of vaccines to high-risk adults, HBV still requires intensive attention as a public health problem. HCV, lacking a vaccine has been evaluated as an infectious agent that needs to be taken into consideration due to its potential risks and requires the complete implementation of individual and social precautions.
Asunto(s)
Antígenos de Superficie de la Hepatitis B , Hepatitis B , Hepatitis C , Hepatitis D , Humanos , Estudios Seroepidemiológicos , Hepatitis D/epidemiología , Hepatitis D/inmunología , Factores de Riesgo , Femenino , Masculino , Estudios Transversales , Persona de Mediana Edad , Adulto , Hepatitis C/epidemiología , Hepatitis B/epidemiología , Turquía/epidemiología , Antígenos de Superficie de la Hepatitis B/sangre , Modelos Logísticos , Anciano , Anticuerpos contra la Hepatitis B/sangre , Adulto Joven , Anticuerpos contra la Hepatitis C/sangre , Adolescente , Anticuerpos Antihepatitis/sangreRESUMEN
This study assesses the prevalence of hepatitis D virus (HDV) in people living with HIV (PLWHIV) in Greece. Given the compounding effects of HDV and hepatitis B (HBV) on liver disease progression, as well as the emergence of new therapeutic options such as bulevirtide, understanding regional disparities and the epidemiological impact of such co-infections is vital. A cross-sectional analysis was conducted utilizing 696 serum samples from PLWHIV attending five major university hospitals. The methodology included HDV antibody detection by ELISA and HDV RNA confirmation. Of the 30 HBsAg-positive samples analyzed, the study population was primarily male (93%), with a median age of 54 years. Participants had been on antiretroviral therapy for a median of 10 years, and the median CD4 count was 738 (539-1006) copies/mL. Additional serological findings revealed a 7% prevalence of hepatitis C virus (HCV) IgG antibodies and a 55% prevalence of hepatitis A virus (HAV) IgG antibodies. Seroreactivity for syphilis (RPR/VDRL/TPHA positive) was identified in 33% of the participants. The results indicated a low HDV prevalence, with only one individual (3%) testing positive for anti-HDV IgG antibodies and none for HDV RNA. This indicates a lower prevalence of HDV among PLWHIV with chronic HBV in Greece compared to global data.
Asunto(s)
Coinfección , Infecciones por VIH , Anticuerpos Antihepatitis , Hepatitis D , Virus de la Hepatitis Delta , Humanos , Estudios Transversales , Masculino , Infecciones por VIH/epidemiología , Infecciones por VIH/virología , Hepatitis D/epidemiología , Femenino , Persona de Mediana Edad , Proyectos Piloto , Grecia/epidemiología , Virus de la Hepatitis Delta/inmunología , Virus de la Hepatitis Delta/genética , Adulto , Prevalencia , Coinfección/epidemiología , Coinfección/virología , Anticuerpos Antihepatitis/sangre , Anciano , ARN Viral/sangre , Estudios SeroepidemiológicosRESUMEN
Hepatitis E virus (HEV) is the most common cause of acute viral hepatitis in the world and can lead to severe complications in immunocompromised individuals. HEV is primarily transmitted through eating pork, which has led to an increased in anti-HEV IgG seropositivity in the general population of Europe in particular. However, it can also be transmitted intravenously, such as through transfusions. The growing evidence of HEV contamination of blood products and documented cases of transmission have given rise to practice changes and blood product screening of HEV in many European countries. This review covers the abundant European literature and focuses on the most recent data pertaining to the prevalence of HEV RNA positivity and IgG seropositivity in the North American general population and in blood products from Canada and the United States. Currently, Health Canada and the Food and Drug Administration do not require testing of HEV in blood products. For this reason, awareness among blood product prescribers about the possibility of HEV transmission through blood products is crucial. However, we also demonstrate that the province of Quebec has a prevalence of anti-HEV and HEV RNA positivity similar to some European countries. In light of this, we believe that HEV RNA blood donation screening be reevaluated with the availability of more cost-effective assays.
Asunto(s)
Donantes de Sangre , Selección de Donante , Virus de la Hepatitis E , Hepatitis E , Humanos , Hepatitis E/epidemiología , Hepatitis E/diagnóstico , Hepatitis E/transmisión , Canadá/epidemiología , Estados Unidos/epidemiología , Virus de la Hepatitis E/aislamiento & purificación , Virus de la Hepatitis E/inmunología , Selección de Donante/métodos , ARN Viral/sangre , Tamizaje Masivo/métodos , Prevalencia , Anticuerpos Antihepatitis/sangre , Seguridad de la Sangre , Inmunoglobulina G/sangre , Donación de SangreRESUMEN
The aim of this research was to define the prevalence of antibodies against hepatitis D virus (anti-HDV Ab) in a group of 26 outpatients with liver dysfunction in northeastern Bulgaria. Serum samples were obtained from April 2022 to December 2023 in the "Status" Medical Diagnostic Laboratory, Varna, Bulgaria. We found seroprevalence of anti-HDV Ab in 15.4% (CI: 4.3-34.8%) of the target population. Age and gender had no significant role in HDV seropositivity.
Asunto(s)
Hepatitis D , Virus de la Hepatitis Delta , Pacientes Ambulatorios , Humanos , Bulgaria/epidemiología , Estudios Seroepidemiológicos , Masculino , Femenino , Hepatitis D/epidemiología , Persona de Mediana Edad , Adulto , Virus de la Hepatitis Delta/inmunología , Anciano , Hepatopatías/epidemiología , Hepatopatías/virología , Adulto Joven , Anticuerpos Antihepatitis/sangreRESUMEN
Previous studies reported that the hepatitis C virus (HCV) could help disseminate the hepatitis D virus (HDV) in vivo through the unrelated hepatitis B virus (HBV), but with essentially inconclusive results. To try to shed light on this still-debated topic, 146 anti-HCV-positive subjects (of whom 91 HCV/HIV co-infected, and 43 with prior HCV eradication) were screened for anti-HDV antibodies (anti-HD), after careful selection for negativity to any serologic or virologic marker of current or past HBV infection. One single HCV/HIV co-infected patient (0.7%) tested highly positive for anti-HD, but with no positive HDV-RNA. Her husband, in turn, was a HCV/HIV co-infected subject with a previous contact with HBV. While conducting a thorough review of the relevant literature, the authors attempted to exhaustively describe the medical history of both the anti-HD-positive patient and her partner, believing it to be the key to dissecting the possible complex mechanisms of HDV transmission from one subject to another, and speculating that in the present case, it may have been HCV itself that behaved as an HDV helper virus. In conclusion, this preliminary research, while needing further validation in large prospective studies, provided some further evidence of a role of HCV in HDV dissemination in humans.
Asunto(s)
Coinfección , Hepacivirus , Hepatitis C , Hepatitis D , Virus de la Hepatitis Delta , Humanos , Hepatitis D/virología , Virus de la Hepatitis Delta/genética , Virus de la Hepatitis Delta/fisiología , Hepacivirus/genética , Hepacivirus/fisiología , Femenino , Hepatitis C/virología , Coinfección/virología , Masculino , Virus Helper/fisiología , Anticuerpos Antihepatitis/sangre , Adulto , Persona de Mediana Edad , Infecciones por VIH/virología , Infecciones por VIH/complicaciones , ARN Viral , Hepatitis B/virologíaRESUMEN
Hepatitis E virus (HEV) is an important cause of acute hepatitis, however, is highly neglected and largely underreported. This study aimed to describe the detailed epidemiology of hepatitis E (HE) through a 10-year surveillance. A community-based active hepatitis surveillance was conducted between November 2007 and October 2017 in 11 townships of Dongtai City in China, involving 355,673 residents. Serum samples were obtained from patients presenting with hepatitis symptoms for more than 3 days. Serum alanine aminotransferase (ALT) levels greater than 2.5 times the upper limit of normal (ULN) were considered acute hepatitis. Samples were subsequently tested for IgG and IgM anti-HEV antibodies, HEV RNA, and hepatitis B surface antigen (HBsAg). The data indicated the incidence of HE fluctuated downward from 2007 to 2017, with an average annual age-standardized incidence of 17.50 per 100,000, exceeding the 10.26 per 100,000 in the National Notifiable Disease Report System (NNDRS). The incidence was notably higher among males (20.95 per 100,000) and individuals aged 50-69 years (37.47 per 100,000). Genotype 4 (HEV-4) was the predominantly circulating genotype during the study period. Furthermore, the study revealed the incidence of hepatitis with HEV and hepatitis B virus (HBV) co-infection was 4.99 per 100,000. The active surveillance system identified a higher incidence of HE compared to NNDRS, with a decreased prevalence over a 10-year period. While efforts are still needed to prevent HE in high-risk populations, including individuals with hepatitis B and the elderly.
Asunto(s)
Anticuerpos Antihepatitis , Virus de la Hepatitis E , Hepatitis E , Humanos , Hepatitis E/epidemiología , Hepatitis E/virología , China/epidemiología , Masculino , Persona de Mediana Edad , Virus de la Hepatitis E/genética , Virus de la Hepatitis E/inmunología , Virus de la Hepatitis E/clasificación , Virus de la Hepatitis E/aislamiento & purificación , Femenino , Adulto , Anciano , Adolescente , Adulto Joven , Incidencia , Niño , Preescolar , Anticuerpos Antihepatitis/sangre , Genotipo , Lactante , Hepatitis B/epidemiología , Hepatitis B/virología , ARN Viral/genética , Coinfección/epidemiología , Coinfección/virología , Inmunoglobulina M/sangre , Monitoreo Epidemiológico , Anciano de 80 o más Años , Inmunoglobulina G/sangre , Virus de la Hepatitis B/genética , Virus de la Hepatitis B/inmunología , Virus de la Hepatitis B/aislamiento & purificación , Antígenos de Superficie de la Hepatitis B/sangre , Recién Nacido , Ciudades/epidemiologíaRESUMEN
INTRODUCTION: Hepatitis E virus (HEV) genotype 3 is the major cause of acute viral hepatitis in several European countries. It is acquired mainly by ingesting contaminated pork, but has also been reported to be transmitted through blood transfusion. Although most HEV infections, including those via blood products, are usually self-limiting, they may become chronic in immunocompromised persons. It is thus essential to identify HEV-infected blood donations to prevent transmission to vulnerable recipients. AIMS: Prior to the decision whether to introduce HEV RNA screening for all Swiss blood donations, a 2-year nationwide prevalence study was conducted. METHODS: All blood donations were screened in pools of 12-24 samples at five regional blood donation services, and HEV RNA-positive pools were subsequently resolved to the individual donation index donation (X). The viral load, HEV IgG and IgM serology, and HEV genotype were determined. Follow-up investigations were conducted on future control donations (X + 1) and previous archived donations of the donor (X - 1) where available. RESULTS: Between October 2018 and September 2020, 541,349 blood donations were screened and 125 confirmed positive donations were identified (prevalence 1:4331 donations). At the time of blood donation, the HEV RNA-positive individuals were symptom-free. The median viral load was 554 IU/mL (range: 2.01-2,500,000 IU/mL). Men (88; 70%) were more frequently infected than women (37; 30%), as compared with the sex distribution in the Swiss donor population (57% male/43% female, p < 0.01). Of the 106 genotyped cases (85%), all belonged to genotype 3. Two HEV sub-genotypes predominated; 3h3 (formerly 3s) and 3c. The remaining sub-genotypes are all known to circulate in Europe. Five 3ra genotypes were identified, this being a variant associated with rabbits. In total, 85 (68%) X donations were negative for HEV IgM and IgG. The remaining 40 (32%) were positive for HEV IgG and/or IgM, and consistent with an active infection. We found no markers of previous HEV in 87 of the 89 available and analyzed archive samples (X - 1). Two donors were HEV IgG-positive in the X - 1 donation suggesting insufficient immunity to prevent HEV reinfection. Time of collection of the 90 (72%) analyzed X + 1 donations varied between 2.9 and 101.9 weeks (median of 35 weeks) after X donation. As expected, none of those tested were positive for HEV RNA. Most donors (89; 99%) were positive for anti-HEV lgG/lgM (i.e., seroconversion). HEV lgM-positivity (23; 26%) indicates an often-long persistence of lgM antibodies post-HEV infection. CONCLUSION: The data collected during the first year of the study provided the basis for the decision to establish mandatory HEV RNA universal screening of all Swiss blood donations in minipools, a vital step in providing safer blood for all recipients, especially those who are immunosuppressed.
Asunto(s)
Donantes de Sangre , Genotipo , Virus de la Hepatitis E , Hepatitis E , ARN Viral , Humanos , Hepatitis E/epidemiología , Hepatitis E/transmisión , Hepatitis E/virología , Donantes de Sangre/estadística & datos numéricos , Suiza/epidemiología , Virus de la Hepatitis E/genética , Virus de la Hepatitis E/inmunología , Virus de la Hepatitis E/clasificación , Virus de la Hepatitis E/aislamiento & purificación , Masculino , Femenino , Adulto , Prevalencia , Persona de Mediana Edad , ARN Viral/genética , ARN Viral/sangre , Anticuerpos Antihepatitis/sangre , Inmunoglobulina M/sangre , Adulto Joven , Inmunoglobulina G/sangre , Carga Viral , Anciano , AdolescenteRESUMEN
The burden of hepatitis E in Southeast Asia is substantial, influenced by its distinct socio-economic and environmental factors, as well as variations in healthcare systems. The aim of this study was to assess the pooled seroprevalence of hepatitis E across countries within the Southeast Asian region by the UN division.The study analyzed 66 papers across PubMed, Web of Science, and Scopus databases, encompassing data from of 44,850 individuals focusing on anti-HEV seroprevalence. The investigation spanned nine countries, excluding Brunei and East Timor due to lack of data. The pooled prevalence of anti-HEV IgG was determined to be 21.03%, with the highest prevalence observed in Myanmar (33.46%) and the lowest in Malaysia (5.93%). IgM prevalence was highest in Indonesia (12.43%) and lowest in Malaysia (0.91%). The study stratified populations into high-risk (farm workers, chronic patients) and low-risk groups (general population, blood donors, pregnant women, hospital patients). It revealed a higher IgG-28.9%, IgM-4.42% prevalence in the former group, while the latter group exhibited figures of 17.86% and 3.15%, respectively, indicating occupational and health-related vulnerabilities to HEV.A temporal analysis (1987-2023), indicated an upward trend in both IgG and IgM prevalence, suggesting an escalating HEV burden.These findings contribute to a better understanding of HEV seroprevalence in Southeast Asia, shedding light on important public health implications and suggesting directions for further research and intervention strategies.Key pointsResearch QuestionInvestigate the seroprevalence of hepatitis E virus (HEV) in Southeast Asian countries focusing on different patterns, timelines, and population cohorts.FindingsSporadic Transmission of IgG and IgM Prevalence:⢠Pooled anti-HEV IgG prevalence: 21.03%⢠Pooled anti-HEV IgM prevalence: 3.49%Seroprevalence among specific groups:High-risk group (farm workers and chronic patients):⢠anti-HEV IgG: 28.9%⢠anti-HEV IgM: 4.42%Low-risk group (general population, blood donors, pregnant women, hospital patients):⢠anti-HEV IgG: 17.86%⢠anti-HEV IgM: 3.15%Temporal Seroprevalence of HEV:Anti-HEV IgG prevalence increased over decades (1987-1999; 2000-2010; 2011-2023): 12.47%, 18.43%, 29.17% as an anti-HEV IgM prevalence: 1.92%, 2.44%, 5.27%ImportanceProvides a comprehensive overview of HEV seroprevalence in Southeast Asia.Highlights variation in seroprevalence among different population groups.Reveals increasing trend in HEV seroprevalence over the years.Distinguishes between sporadic and epidemic cases for a better understanding of transmission dynamics.
Asunto(s)
Anticuerpos Antihepatitis , Virus de la Hepatitis E , Hepatitis E , Inmunoglobulina G , Inmunoglobulina M , Hepatitis E/epidemiología , Hepatitis E/sangre , Humanos , Estudios Seroepidemiológicos , Virus de la Hepatitis E/inmunología , Inmunoglobulina M/sangre , Inmunoglobulina G/sangre , Anticuerpos Antihepatitis/sangre , Asia Sudoriental/epidemiología , Femenino , Prevalencia , Factores de Riesgo , Masculino , EmbarazoRESUMEN
BACKGROUND: HDV antibody testing is recommended for universal screening and as the first line in an HDV double reflex testing strategy for effectively identifying patients with active infection for therapeutic treatments. OBJECTIVE: The aim of this study is to evaluate the performance of a newly developed ARCHITECT HDV Total Ig (ARCHITECT HDV Ig) prototype assay. STUDY DESIGN: Performance characteristics were determined for the ARCHITECT HDV Ig and a reference test, LIAISON XL Anti-HDV using a well-characterized specimen panel, comprising HDV RNA positive (n = 62) and negative (n = 70) samples, and healthy US blood donors. RESULTS: Healthy US blood donors (n=200) showed 99.5% (199/200, 95%CI=97.65-99.98) specificity with ARCHITECT HDV Ig and 98.5 % (197/200, 95 %CI = 96.10-99.64) with LIAISON Anti-HDV. Among known HDV RNA positive samples, ARCHITECT HDV Ig detected 59/62 demonstrating 95.2 % sensitivity while LIAISON Anti-HDV sensitivity was 90.3 % (56/62). Among 101 HBV positive samples, 70 were reactive in the ARCHITECT test, 59 of which tested positive for HDV RNA for a positive predictive value (PPV) for the presence of HDV RNA was 84.3 %. For LIAISON Anti-HDV, 79 specimens were reactive and 56 contained HDV RNA: PPV for HDV RNA was 70.9 %. Among 70 HDV RNA negative samples, 39 were HBV positive. ARCHITECT HDV Ig negative predictive value (NPV) was 71.8 % and LIAISON Anti-HDV NPV was 41 % for the HBV positive group, respectively. CONCLUSION: When compared to the LIASON Anti-HDV test, the ARCHITECT HDV Ig assay demonstrated enhanced sensitivity and specificity and better NPV and PPV values for HDV RNA status. The ARCHITECT HDV Ig assay represents a promising tool for universal screening of all HBsAg-positive persons.
Asunto(s)
Anticuerpos Antihepatitis , Hepatitis D , Virus de la Hepatitis Delta , Ensayos Analíticos de Alto Rendimiento , Sensibilidad y Especificidad , Humanos , Hepatitis D/diagnóstico , Hepatitis D/inmunología , Virus de la Hepatitis Delta/inmunología , Virus de la Hepatitis Delta/genética , Virus de la Hepatitis Delta/aislamiento & purificación , Anticuerpos Antihepatitis/sangre , Ensayos Analíticos de Alto Rendimiento/métodos , Pruebas Serológicas/métodos , Automatización de Laboratorios/métodos , Donantes de SangreRESUMEN
Patients living with HIV infection (PLWH) are at risk of acquiring HBV and HDV. The present study aimed to determine the prevalence and characteristics of HIV-HDV-HBV tri-infection in comparison with HIV-HBV coinfection and to estimate severities and outcomes of associated liver diseases in Mauritanian PLWH. Two-hundred-ninety-two consecutive HBsAg-positive PLWH were included (mean age: 37 years). Clinical data were recorded. Anti-HDV antibodies, HBV and HDV viral loads (VLs) and genotype were determined. APRI, FIB-4 and FibroScan were performed to evaluate the severity of liver disease. The anti-HDV antibodies prevalence was 37% and HDV RNA was positive in 40.7% of patients. Genetic diversities were found with HDV genotype 1 (93%) and HBV genotypes D (42.5%) and E (38%). The HBV VL was detectable in 108 patients at inclusion, and mutations associated with HBV resistance were found in 20. For almost all variables studied, including FIB-4 and APRI scores, no significant differences were found between anti-HDV-Ab positive or negative patients. FibroScan examination, which was performed in 110 patients at end-of-follow-up showed higher, but NS values, in HDV positive patients. After a mean follow-up of 24.55 ± 8.01 months (n = 217 patients), a highly significant worsening of APRI and FIB-4 scores was found. Moreover, patients with HDV showed more severe liver disease progression despite an efficient therapy. In a substantial Mauritanian cohort of relatively young PLWH, we found high HDV prevalence and worsening liver disease. In high-risk countries, screening for HDV and providing appropriate follow-up and treatments are warranted in PLWH.
Asunto(s)
Coinfección , Infecciones por VIH , Anticuerpos Antihepatitis , Hepatitis D , Virus de la Hepatitis Delta , Carga Viral , Humanos , Mauritania/epidemiología , Infecciones por VIH/complicaciones , Infecciones por VIH/epidemiología , Masculino , Adulto , Femenino , Prevalencia , Virus de la Hepatitis Delta/genética , Anticuerpos Antihepatitis/sangre , Coinfección/epidemiología , Coinfección/virología , Hepatitis D/epidemiología , Hepatitis D/complicaciones , Persona de Mediana Edad , Pronóstico , Hepatitis B/epidemiología , Hepatitis B/complicaciones , Hepatitis B/virología , Genotipo , Adulto Joven , Virus de la Hepatitis B/genéticaRESUMEN
Hepatitis E virus (HEV) infects roughly 20 million people worldwide, causing self-limiting acute hepatic disease that can evolve into a chronic course. HEV-3, HEV-4, and HEV-7 genotypes are zoonotic and transmitted to humans by consuming raw or undercooked meat. Here, we developed an indirect ELISA based on the recombinant HEV-3 capsid and performed a seroprevalence study on domestic swine in northeastern Brazil. Our in-house ELISA was initially validated using a subset of 79 sera characterized by concordant results for two distinct commercial ELISA kits. Our ELISA exhibited excellent sensitivity (94%) and specificity (100%), with an area under the curve of 0.99 Further testing, including 212 swine sera, revealed a seroprevalence of 57.5% (95% confidence interval, 50.6-64.3%). Our findings indicate that the novel ELISA test could accurately detect specific anti-HEV antibodies in domestic pigs and should be further validated in humans and other mammals.
Asunto(s)
Ensayo de Inmunoadsorción Enzimática , Virus de la Hepatitis E , Hepatitis E , Pruebas Serológicas , Enfermedades de los Porcinos , Animales , Hepatitis E/veterinaria , Hepatitis E/diagnóstico , Hepatitis E/epidemiología , Ensayo de Inmunoadsorción Enzimática/veterinaria , Ensayo de Inmunoadsorción Enzimática/métodos , Porcinos , Virus de la Hepatitis E/inmunología , Virus de la Hepatitis E/genética , Virus de la Hepatitis E/aislamiento & purificación , Enfermedades de los Porcinos/diagnóstico , Enfermedades de los Porcinos/virología , Estudios Seroepidemiológicos , Pruebas Serológicas/veterinaria , Brasil/epidemiología , Anticuerpos Antihepatitis/sangre , Sensibilidad y Especificidad , HumanosRESUMEN
To determine the kinetics of hepatitis E virus (HEV) in asymptomatic persons and to evaluate viral load doubling time and half-life, we retrospectively tested samples retained from 32 HEV RNA-positive asymptomatic blood donors in Germany. Close-meshed monitoring of viral load and seroconversion in intervals of ≈4 days provided more information about the kinetics of asymptomatic HEV infections. We determined that a typical median infection began with PCR-detectable viremia at 36 days and a maximum viral load of 2.0 × 104 IU/mL. Viremia doubled in 2.4 days and had a half-life of 1.6 days. HEV IgM started to rise on about day 33 and peaked on day 36; IgG started to rise on about day 32 and peaked on day 53. Although HEV IgG titers remained stable, IgM titers became undetectable in 40% of donors. Knowledge of the dynamics of HEV viremia is useful for assessing the risk for transfusion-transmitted hepatitis E.
Asunto(s)
Donantes de Sangre , Virus de la Hepatitis E , Hepatitis E , ARN Viral , Carga Viral , Viremia , Humanos , Hepatitis E/epidemiología , Hepatitis E/virología , Virus de la Hepatitis E/genética , Virus de la Hepatitis E/inmunología , Masculino , Adulto , Inmunoglobulina M/sangre , Femenino , Inmunoglobulina G/sangre , Cinética , Persona de Mediana Edad , Infecciones Asintomáticas/epidemiología , Estudios Retrospectivos , Anticuerpos Antihepatitis/sangre , Alemania/epidemiología , Adulto JovenRESUMEN
Hepatitis E virus (HEV) is the main cause of acute hepatitis in humans worldwide and is responsible for a large number of outbreaks especially in Africa. Human infections are mainly caused by genotypes 1 and 2 of the genus Paslahepevirus, which are exclusively associated with humans. In contrast, viruses of genotypes 3 and 4 are zoonotic and have their main reservoir in domestic and wild pigs, from which they can be transmitted to humans primarily through the consumption of meat products. Both genotypes 3 and 4 are widespread in Europe, Asia, and North America and lead to sporadic cases of hepatitis E. However, there is little information available on the prevalence of these genotypes and possible transmission routes from animal reservoirs to humans in African countries. We therefore analysed 1086 pig sera collected in 2016/2017 in four districts in Sierra Leone for antibodies against HEV using a newly designed in-house ELISA. In addition, the samples were also analysed for HEV RNA by quantitative real-time RT-PCR. The overall seroprevalence in Sierra Leone was low with only 44 positive sera and a prevalence of 4.0%. Two serum pools were RT-PCR-positive and recovered partial sequences clustered into the genotype 3 (HEV-3) of the order Paslahepevirus, species Paslahepevirus balayani. The results are the first evidence of HEV-3 infection in pigs from Sierra Leone and demonstrate a low circulation of the virus in these animals to date. Further studies should include an examination of humans, especially those with close contact with pigs and porcine products, as well as environmental sampling to evaluate public health effects within the framework of a One Health approach.
Asunto(s)
Genotipo , Virus de la Hepatitis E , Hepatitis E , Filogenia , Enfermedades de los Porcinos , Animales , Hepatitis E/epidemiología , Hepatitis E/veterinaria , Hepatitis E/virología , Virus de la Hepatitis E/genética , Virus de la Hepatitis E/clasificación , Virus de la Hepatitis E/aislamiento & purificación , Virus de la Hepatitis E/inmunología , Estudios Seroepidemiológicos , Porcinos , Enfermedades de los Porcinos/virología , Enfermedades de los Porcinos/epidemiología , Sierra Leona/epidemiología , Anticuerpos Antihepatitis/sangre , ARN Viral/genética , Sus scrofa/virología , HumanosRESUMEN
Foreign-born (FB) persons represent a large proportion of adults with chronic hepatitis B (CHB) in Canada due to higher prevalence rates in countries of birth for FB persons. Suboptimal awareness and low rates of hepatitis delta virus (HDV) testing contribute to underdiagnosis and gaps in accurate estimates of Canada HDV prevalence. We aim to provide an assessment of CHB and HDV prevalence in Canada using a comprehensive literature review and meta-analysis. A comprehensive literature review of articles reporting HBsAg seroprevalence and anti-HDV prevalence was conducted to calculate country-specific rates and pooled prevalence of CHB and HDV using meta-analyses. Country-specific CHB and HDV rate estimates were combined with number of FB persons in Canada in 2021 from Statistics Canada to estimate total numbers of FB with CHB and HDV, respectively. These estimates were combined with estimates of Canada-born persons with CHB and HDV to yield the total number of persons with CHB and HDV. In 2021, we estimated 0.550 million (M) (95% CI 0.488-0.615) persons with CHB; 0.344 M (95% CI 0.288-0.401) were FB and 0.206 M (95% CI: 0.200-0.214) were Canada-born. The weighted average HDV prevalence among FB persons in Canada was 5.19% (17,848 [95% CI 9611-26,052] persons), among whom 50% emigrated from Asia and 31% from Africa. When combined with estimates of Canada-born persons with HDV, we estimate 35,059 (95% CI: 18,744-52,083) persons with HDV in Canada. In conclusion, we estimate 0.550 M and 35,059 persons living with CHB and HDV, respectively, in Canada in 2021.
Asunto(s)
Hepatitis D , Virus de la Hepatitis Delta , Humanos , Canadá/epidemiología , Prevalencia , Hepatitis D/epidemiología , Virus de la Hepatitis Delta/inmunología , Adulto , Estudios Seroepidemiológicos , Emigrantes e Inmigrantes/estadística & datos numéricos , Hepatitis B Crónica/epidemiología , Antígenos de Superficie de la Hepatitis B/sangre , Anticuerpos Antihepatitis/sangre , MasculinoRESUMEN
We explored the association between serological status for hepatitis E and neurocysticercosis (NCC) in neurologic patients attending a national neurological referral center in Lima, Perú, between the years 2008 and 2012. Anti-hepatitis E antibodies were evaluated in patients with and without NCC, and a control group of rural general population. Anti-hepatitis E IgG was found in 23.8% of patients with NCC, compared with 14.3% in subjects without NCC from a general rural population (P = 0.023) and 14.4% in subjects with neurological complaints without NCC (P = 0.027). Seropositive patients had a median age of 44 years compared with 30 years in seronegative patients (P <0.001). No significant differences in sex, region of residence, or liver enzyme values were found. Seropositivity to hepatitis E was frequent in this Peruvian population and higher in patients with NCC, suggesting shared common routes of infection.
Asunto(s)
Virus de la Hepatitis E , Hepatitis E , Neurocisticercosis , Humanos , Neurocisticercosis/epidemiología , Neurocisticercosis/inmunología , Neurocisticercosis/complicaciones , Masculino , Adulto , Femenino , Hepatitis E/epidemiología , Hepatitis E/inmunología , Virus de la Hepatitis E/inmunología , Persona de Mediana Edad , Perú/epidemiología , Adulto Joven , Prevalencia , Inmunoglobulina G/sangre , Anticuerpos Antihepatitis/sangre , Estudios Seroepidemiológicos , Adolescente , AncianoRESUMEN
Transfusion-transmitted hepatitis E virus (HEV) infection is an increasing concern in many countries. We investigated the detection rate of HEV viremia in blood donors in Russia. A total of 20,405 regular repetitive voluntary non-renumerated blood donors from two regions (Moscow and Belgorod) were screened for HEV RNA using the cobas® HEV test in mini-pools of six plasma samples. Samples from each reactive pool were tested individually. The average HEV RNA prevalence was 0.024% (95% CI: 0.01-0.05%), or 1 case per 4081 donations. No statistically significant differences in HEV RNA prevalence were observed between the two study regions. The PCR threshold cycle (Ct) values ranged from 25.0 to 40.5 in reactive pools, and from 20.9 to 41.4 in reactive plasma samples when tested individually. The HEV viremic donors had different antibody patterns. Two donor samples were reactive for both anti-HEV IgM and IgG antibodies, one sample was reactive for anti-HEV IgM and negative for anti-HEV IgG, and two samples were seronegative. At follow-up testing 6 months later, on average, four donors available for follow-up had become negative for HEV RNA and positive for anti-HEV IgG. The HEV ORF2 sequence belonging to HEV-3 sub-genotype 3a was obtained from one donor sample. The sequencing failed in the other four samples from viremic donors, presumably due to the low viral load. In conclusion, the HEV RNA detection rate in blood donors in Russia corresponds with data from other European countries, including those that implemented universal donor HEV screening. These data support the implementation of HEV RNA donor screening to reduce the risk of transfusion-transmitted HEV infection in Russia.
Asunto(s)
Donantes de Sangre , Anticuerpos Antihepatitis , Virus de la Hepatitis E , Hepatitis E , ARN Viral , Humanos , Hepatitis E/epidemiología , Hepatitis E/transmisión , Hepatitis E/virología , Virus de la Hepatitis E/genética , Virus de la Hepatitis E/inmunología , Virus de la Hepatitis E/aislamiento & purificación , Federación de Rusia/epidemiología , ARN Viral/sangre , Masculino , Adulto , Femenino , Anticuerpos Antihepatitis/sangre , Persona de Mediana Edad , Viremia/epidemiología , Adulto Joven , Inmunoglobulina M/sangre , Filogenia , Prevalencia , Inmunoglobulina G/sangre , GenotipoRESUMEN
Background: Hepatitis E virus (HEV) is transmitted by the fecal route, usually through contaminated water in humans and/or infected animals, especially pigs. The objective of this study was to evaluate the level of anti-HEV antibodies in a panel of pig sera and to identify HEV in pig feces in farms. Methodology: The presence of HEV antibodies was tested by an in-house ELISA and a commercial ELISA IDvet. HEV genome was assessed by nested RT-PCR, and then, genotype was identified by sequencing (MinION Nanopore technology). Results: In 2017-2019, the 43% seroprevalence found in Forest Guinea was significantly higher than the 7% found in the Lower region (p < 0.01). Presence of HEV genotype 3c was demonstrated during a secondary study in the Lower region (Conakry) in 2022. Conclusion: The presence of HEV-3c in pigs calls for an evaluation of seroprevalence in human populations and for a HEV genotype human circulation check. Contribution Heading: This study is the first report, to our knowledge, of seroprevalence and characterization of HEV infection in pigs in Guinea.
Asunto(s)
Virus de la Hepatitis E , Hepatitis E , Filogenia , Enfermedades de los Porcinos , Animales , Virus de la Hepatitis E/genética , Virus de la Hepatitis E/aislamiento & purificación , Virus de la Hepatitis E/clasificación , Virus de la Hepatitis E/inmunología , Estudios Seroepidemiológicos , Hepatitis E/epidemiología , Hepatitis E/veterinaria , Hepatitis E/virología , Porcinos , Enfermedades de los Porcinos/epidemiología , Enfermedades de los Porcinos/virología , Cobayas , Guinea/epidemiología , Heces/virología , Anticuerpos Antihepatitis/sangre , GenotipoRESUMEN
Hepatitis E virus (HEV) is a major cause of acute jaundice in South Asia. Gaps in our understanding of transmission are driven by non-specific symptoms and scarcity of diagnostics, impeding rational control strategies. In this context, serological data can provide important proxy measures of infection. We enrolled a population-representative serological cohort of 2,337 individuals in Sitakunda, Bangladesh. We estimated the annual risks of HEV infection and seroreversion both using serostatus changes between paired serum samples collected 9 months apart, and by fitting catalytic models to the age-stratified cross-sectional seroprevalence. At baseline, 15% (95 CI: 14-17%) of people were seropositive, with seroprevalence highest in the relatively urban south. During the study, 27 individuals seroreverted (annual seroreversion risk: 15%, 95 CI: 10-21%), and 38 seroconverted (annual infection risk: 3%, 95CI: 2-5%). Relying on cross-sectional seroprevalence data alone, and ignoring seroreversion, underestimated the annual infection risk five-fold (0.6%, 95 CrI: 0.5-0.6%). When we accounted for the observed seroreversion in a reversible catalytic model, infection risk was more consistent with measured seroincidence. Our results quantify HEV infection risk in Sitakunda and highlight the importance of accounting for seroreversion when estimating infection incidence from cross-sectional seroprevalence data.